Lyra Therapeutics Inc (NASDAQ: LYRA)’s stock price has decreased by -5.92 compared to its previous closing price of 0.22. However, the company has seen a -1.41% decrease in its stock price over the last five trading sessions. zacks.com reported 2024-11-12 that Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.27 per share a year ago.
Is It Worth Investing in Lyra Therapeutics Inc (NASDAQ: LYRA) Right Now?
The stock has a 36-month beta value of -0.13. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for LYRA is 54.79M, and at present, short sellers hold a 3.35% of that float. On January 08, 2025, the average trading volume of LYRA was 1.95M shares.
LYRA’s Market Performance
The stock of Lyra Therapeutics Inc (LYRA) has seen a -1.41% decrease in the past week, with a -5.30% drop in the past month, and a -6.91% fall in the past quarter. The volatility ratio for the week is 13.74%, and the volatility levels for the past 30 days are at 12.12% for LYRA. The simple moving average for the past 20 days is 4.65% for LYRA’s stock, with a -79.79% simple moving average for the past 200 days.
Analysts’ Opinion of LYRA
Many brokerage firms have already submitted their reports for LYRA stocks, with Jefferies repeating the rating for LYRA by listing it as a “Hold.” The predicted price for LYRA in the upcoming period, according to Jefferies is $0.50 based on the research report published on May 07, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LYRA reach a price target of $2, previously predicting the price at $12. The rating they have provided for LYRA stocks is “Neutral” according to the report published on May 07th, 2024.
LYRA Trading at -4.11% from the 50-Day Moving Average
After a stumble in the market that brought LYRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.00% of loss for the given period.
Volatility was left at 12.12%, however, over the last 30 days, the volatility rate increased by 13.74%, as shares sank -5.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.93% lower at present.
During the last 5 trading sessions, LYRA fell by -3.05%, which changed the moving average for the period of 200-days by -96.79% in comparison to the 20-day moving average, which settled at $0.1943. In addition, Lyra Therapeutics Inc saw -1.41% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LYRA
Current profitability levels for the company are sitting at:
- -68.94 for the present operating margin
- -8.17 for the gross margin
The net margin for Lyra Therapeutics Inc stands at -66.36. The total capital return value is set at -1.59. Equity return is now at value -186.18, with -97.94 for asset returns.
Currently, EBITDA for the company is -65.25 million with net debt to EBITDA at -0.17. When we switch over and look at the enterprise to sales, we see a ratio of 16.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.64.
Conclusion
To sum up, Lyra Therapeutics Inc (LYRA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
